

Supplementary results

HBx may be acquired by zoonotic spillover

To explain why HBx may be present in UC patients, we supposed that HBx positivity may be acquired after environmental exposure to this viral entity, for example, during an event of zoonotic spillover.

To corroborate this hypothesis reads belonging to the *Hepadnaviridae* family were searched with Serratus[1] within 3.8 million NGS runs from the NCBI SRA data repository (<https://www.ncbi.nlm.nih.gov/sra>), normalized on the total runs per species (**Supplementary Figure 11A**). Interestingly, half of the runs from *Trichobilharzia*, a notorious human zoonotic agent colonizing water during its zoonotic life cycle [2,3], were found positive, followed by those from *Isatis tinctoria*, a flowering plant found worldwide, and *Odorrana tormota* (Chinese torrent frog) (**Supplementary Figure 11B**). A high number of runs belonging to *Marmota monax* (eastern woodchuck) was highly expected, as this animal is naturally infected with Woodchuck Hepatitis Virus (WHV)[4] (Supplementary Figure 11B). All these organisms, including humans, may accidentally get in contact with *Trichobilharzia*-contaminated water during their lifespan. As mentioned in the main text, it is noteworthy that only mammalian-infecting *Orthohepadnavirus* carries the HBx ORF, thus raising concerns regarding the possibility that *Trichobilharzia*, or the *Isatis tinctoria*, might be at the basis of the HBx zoonotic transmission. Therefore, we searched for the HBx sequence within the runs (**Supplementary Figure 12A**), and we interestingly found that both *Trichobilharzia* and the plant *Isatis tinctoria*, but not *Odorrana tormota*, nor *Elaeagnaceae*, were carrying the HBx encoding sequence (**Supplementary Figures 12B-12E**).

To evaluate the global distribution of *Trichobilharzia* and *Isatis tinctoria*, the Global Biodiversity Information Facility database (<https://www.gbif.org/>) was interrogated to map 404 georeferenced records reported from 1949 to 2022, and we found *Trichobilharzia* spreading in USA, New Zealand, Argentina, South Africa, Canada, North America, East Boreal, France, Asia, Australia, Brazil, Iceland, United Kingdom (Supplementary Figure

12F and Supplementary Table 1), while *Isatis tinctoria* was highly widespread in Europe, including Italy, and USA (Supplementary Figure 12G and Supplementary Table 2).

It has been recently reported that the highest prevalence/incidence of UC occurs in the USA and European countries[5,6]. While being aware this does not still represent a causal link between the environmental exposure to these specific factors and disease pathogenesis, we observed that the UC global burden overlaps the geographical distribution of the *Trichobilharzia* and *Isatis T.* spreading, further supporting a possible association between these events.

Nevertheless, further association studies, and/or systematic reviews, and meta-analyses are required to demonstrate this hypothesis and exclude any *epiphenomenon*.

Supplementary methods

Biopsy collection and patient inclusion criteria

Endoscopic biopsies collected from patients with UC undergoing endoscopy were used. The degree of disease activity active state was diagnosed by physicians based on clinical, endoscopic, and histological criteria. Clinical, endoscopic, and histological severity were assessed using the Mayo clinical score, Mayo endoscopic score[9], and the Riley histological scoring system[10], respectively. Active mucosal biopsies were defined by endoscopic Mayo score ≥ 2 and Riley Index ≥ 3 .

Healthy endoscopic biopsies were negative for anti-HBV antibodies obtained from patients undergoing routine check-ups for non-IBD-related diseases.

All patients were tested according to clinical practice guidelines for anti-HBcAg total (IgM+IgG) HBs levels by chemiluminescent immunoassay (Abbott, Germany) and liver function enzymes. This was a multicenter observational retrospective study enrolling patients from 2008 to 2018 in two clinical centers (Humanitas Research and Clinical Institute, Milan, Italy, and Fondazione IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy) and approved by the independent ethic committees (Protocol number CE Humanitas ex D.M.8/2/2013-183/14, protocol number CE Casa Sollievo Della Sofferenza: 12701/2008). All subjects provided written informed consent.

***In vivo* experiments**

Female C57BL/6 mice were maintained in a specific-pathogen-free (SPF) animal facility and used at 8 weeks of age. All experiments were performed following the guidelines established in the Principle of Laboratory Animal Care (directive 86/609/EEC) and were approved by the Italian Ministry of Health. The procedures involving mice conformed to institutional guidelines in agreement with national and international law and were approved by the ethics committee of the Humanitas Research Hospital. On the basis of our experience with animal models and according to animal-welfare policy (directive 86/609/EEC), which strongly suggests the use of a limited number of animals, we estimated that two experiments with $n=6$ mice per group would allow us to reach statistical significance. Mice were randomized, and experimental mice allocation and evaluation of clinical disease parameters by a dedicated lab technician were blinded.

HBV screening of patients

Anti-HBc antibodies are the best marker for prior exposure to HBV as they become detectable before anti-HBs and remain positive indefinitely after[11]. Moreover, and practical for our study purposes, anti-HBc antibodies are not influenced by prior vaccination (unlike anti-HBs).

Patients positive for anti-HBc antibodies (IgM+IgG) have encountered the virus at a certain point in life and either cleared the infection (roughly in 95% of cases) or have an ongoing chronic infection (5%)[12]. To rule out the latter, anti-HBs testing was performed in all anti-HBc-positive patients, and no chronic infection was found. Moreover, no patient in the whole cohort, regardless of HBV serology, had deranged liver function tests (AST and ALT), further excluding infections, especially acute ones. In addition, the clinical records of all patients were reviewed and no mention was found of any liver abnormalities, HBV infection, other viral hepatitis, or HIV.

Reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing

Total RNA was extracted from the fresh frozen biopsy samples using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA; cat. #217004) and gentleMACS dissociator (Miltenyi Biotec, Bergisch-Gladbach, Germany; cat. #130-096-335) according to manufacturers' instructions. RNA quality was evaluated on the Bioanalyzer 2100 microcapillary electrophoresis system (Agilent Technologies, Palo Alto, CA, USA). Genomic DNA was extracted from endoscopic biopsies or blood by using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA, cat. #69504) according to the manufacturer's instructions.

A mixture containing 0.1 µg of total RNA from each sample was reverse transcribed for 10 min at 25°C, and 2 h at 37°C using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA; cat. #4368814).

For GAPDH, PCR was performed in a final volume of 25 µL containing 2.5 µL 10× PCR Buffer, 2.5mM dNTPs, 25mM MgCl₂, 15pM of forward (5'-GAAGGTGAAGGTCGGAGTC-3') and reverse (5'-GAAGATGGTGATGGGATTTC-3') primers, 0.75U AmpliTaq Gold polymerase (Thermo Fisher Scientific, Waltham, MA, USA; cat. #N808-0245) and 1µL cDNA. Cycling PCR conditions consisted of an initial 10 min denaturation step at 94°C, followed by 35 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 10 min.

For HBx detection, PCR reactions (25µL) were performed in 1X Phusion GC Buffer, 3.5mM MgCl₂, 0.1U Phusion High-Fidelity (Thermo Fisher Scientific, Waltham, Massachusetts, USA; cat. #F530L), 0.2mM for forward (5'-GTGTGCACTTCGCTTCACCT -3') and reverse (5'-GTGCTGGTGAACAGACCAAT-3') primers, 0.5 mM dNTPs, DMSO 4% and 1 µL cDNA (or 25 ng of genomic DNA, when trios were analyzed). After initial denaturation for 30 sec at 98°C, the reaction was subjected to amplification for 12 cycles at 98° C for 30 sec, at 68°C (ending at an annealing temperature of 62°C) for 30 sec and at 72°C for 30 sec. It follows 25 cycles: 98°C for 30 sec, 62°C for 30 sec, and 72°C for 30 sec. The final extension was 72°C for 10 min (**Supplementary Figure 1D**). PCR products were visualized by GelRed Nucleic

Acid Stain (Biotium, Fremont, CA, USA, cat. #41003) on 3% agarose gels in presence of a pGEM DNA marker ladder (Promega, Madison, WI, USA, cat. #G1741).

A sequencing reaction was performed on positive samples, including the negative for further control to verify the correspondence between the amplicons and the selected HBx sequence. Briefly, PCR products were purified with a vacuum system (Millipore, Bedford, MA, USA, cat. #MSNU03050) according to the manufacturer's recommendation. The amplicons were sequenced from both ends using an aliquot (3.2pM) of the PCR reaction primer in presence of BigDye Terminator Cycle Sequencing Kit v. 1.1 (Thermo Fisher Scientific, Waltham, MA, USA, cat. #4337450) according to the manufacturer's recommendation. After purification by using centrisep columns (Princeton Separations, Adelphia, NJ, USA, cat. #CS-901), sequencing reactions were loaded onto 3500 DX Genetic Analyzer capillaries (Applied Biosystems, Waltham, MA, USA) and analyzed using the Sequencing Analysis software v5.4.

Sanger sequencing results are available at OP978007-OP978010 in NCBI GenBank.

Quantitative real-time PCR

Total RNA was extracted from Caco-2 cells and mouse colon tissues using the PureZOL RNA isolation reagent (Bio-Rad, Hercules, CA, USA, cat. #7326890) according to the manufacturer's instructions. RNA retrotranscription was performed with High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Waltham, MA, USA, cat. #11732641001). The quantitative real-time PCR reaction was performed with SYBR® Green Real-Time PCR Master Mix (Thermo Fisher Scientific, Waltham, Massachusetts, USA, cat. #4385610) according to the manufacturer's instructions. The primer pairs used are summarized in **Supplementary Table 4** and **Table 5**. The reactions were performed and analyzed on the ViiA7 Real-Time PCR System (Applied Biosystems, Waltham, Massachusetts, USA). GAPDH expression was used as the housekeeping gene. Data were calculated using the $2^{-\Delta\Delta Ct}$ method.

Serratus and NCBI Blast

The Serratus open-science viral discovery platform was queried for *Hepadnavirus* in March 2022. The total number of SRA reads per species was obtained from NCBI SRA and used to normalize Serratus hits. SRA reads belonging to the top 10 enriched species were then subjected to NCBI Blast[7] to search for the *HBx* coding sequence. Plots were made with ggplot2[8].

Biodiversity data analysis

Georeferenced records for *Trichobilharzia* and *Isatis tinctoria* were downloaded from the Global Biodiversity Information Facility (GBIF, <https://www.gbif.org/>), reshaped with tidyverse[9], and plotted with ggplot2[8].

Molecular cloning

To generate the EF1 α -HBx-IRES-GFP lentiviral vector, the HBx encoding sequence was cloned downstream of the EF1 α promoter and upstream of the IRES sequence in the pHIV-IRES luciferase vector (Addgene, Watertown, MA, USA, cat. plasmid #21375), previously modified by substituting the luciferase sequence with the GFP. The V5-tagged HBx-carrying lentiviral vector was obtained by inserting upstream the V5 tag in the HBx encoding sequence without the stop codon in the pCAG-V5 vector, kindly given by Dr. Alessandro Sessa of the San Raffaele Research Institute. Then, the HBx-V5 sequence was inserted downstream of the EF1 α promoter-carrying lentiviral vector. The EF1 α -GFP vector was used as a control, as previously described[10].

Lentiviral transduction of endoscopic biopsies and cells

Lentiviral particles harboring V5-tagged HBx, HBx-IRES-GFP, or GFP were produced by transient transfection of 293T cells according to standard protocols[11] and as previously described[10]. This cell line is competent for replicating vectors carrying the SV40 region of replication. Mucosal biopsies collected from healthy donors were washed twice in RPMI medium (Lonza, Basel, Switzerland, cat. #12-167Q) supplemented with Fetal Bovine Serum (Euroclone, Pero, Italy, cat. #ECS0186L), UltraGlutamine™ I (Lonza, Basel,

Switzerland, cat. #BE17-605E/U1, final concentration: 2mM), HEPES Buffer (Euroclone, Pero, Italy, cat. #ECM0180D, final concentration: 10mM), and with an antibiotics mixture of Penicillin-Streptomycin-Amphotericin B (Lonza, Basel, Switzerland, cat. #17-745E, final concentration: 100mU/mL; 100mg/mL; 0.25mg/mL), Gentamicin Sulfate (Lonza, Basel, Switzerland, cat. #17-518Z, final concentration: 0.5mg/mL), and Puromycin (Invivogen, San Diego, CA, USA cat. #ant-pr-1, final concentration: 0.1mg/mL). Each biopsy was washed, plated, and transduced with lentiviral particles carrying either the HBx-IRES-GFP or the GFP encoding sequences as control. Transduced biopsies were maintained at 37°C for 48 hours and then washed twice in phosphate-buffered saline (PBS) 1x. Biopsies consequently underwent digestion using collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ, USA, cat. #LS004176, final concentration: 7.5mg/mL), followed by gentle compression through 70µm and 100µm cell strainer (Falcon, Corning, NY, USA, cat. #352350, 352360) to extrude cell clumps. The obtained cellular pool was collected after centrifuge and frozen for the RNA-Seq analysis.

For Caco-2, 1×10^6 cells were transduced with lentiviral particles carrying either the V5-tagged HBx-encoding sequence or the HBx-IRES-GFP or the empty vector as control. For siRNA treatment, Caco-2 cells were transfected with 0.2nmol of HBx-targeting siRNAs or the relative scramble controls, by using Lipofectamine 2000® (Life Technology, Carlsbad, CA) according to the manufacturer's instructions. HBx-targeting siRNA sequences are listed in Supplementary Table 6. For the experiments, siRNA#3, #7, and #8 were used.

Prior to CHIP analysis, cells were then maintained confluent in culture for 72 hours and then processed.

For epithelial organoid transduction, cells were collected in a 15mL tube and treated with a medium containing lentiviral particles carrying either the HBx-IRES-GFP or GFP-encoding sequence for 4 hours at 37°C. After incubation, organoids were washed and centrifuged twice and moved to a 5mL round bottom FACS tube for the following analysis.

Two independent experiments with endoscopic biopsies, Caco-2 cells, and epithelial organoids were performed at least in triplicate.

Epithelial organoid derivation

Healthy donor-derived endoscopic biopsies were collected in PBS1X without calcium and magnesium on ice and washed 3 times in 10mL of Complete Chelating Solution (1X CCS), made of Incomplete Chelating Solution (ICS 5X, 500mL MilliQ H₂O, 2.7g KH₂PO₄, 0.3g KCl, 2.49g Na₂HPO₄-2H₂O, 14g NaCl, 37.5g Sucrose, 25g D-Sorbitol) diluted 1:5 in MilliQ H₂O and supplemented with DTT 0.5μM (PanReac Applichem, Chicago, IL, USA, Cat.#A9448). Biopsies were then incubated at 4°C for 30 minutes in a solution of CCS containing EDTA 0.5M. After digestion, crypts from biopsies were obtained by gentle mechanical dissociation. Crypts were subsequently transferred into a 15mL tube and centrifuged at 800RPM for 5 minutes. The obtained crypt-enriched fraction was resuspended in Matrigel (Corning, New York, NY, USA, cat. #356231)-advanced DMEM/F12 medium (Lonza, Basel, Switzerland, cat. #BE04687F/1) to a ratio of 1:1 and then seeded in a 24-well plate and incubated for 20 minutes at 37°C/5%CO₂ to allow the Matrigel dome to solidify. Afterward, 700uL of WENR culturing medium (**Supplementary Table 7**) was supplemented with Y27632 (Tocris, Bristol, UK, cat. #1254) and CHIR99201 (Tocris, Bristol, UK, cat. #4423) and added to the cell culture. CHIR 99021 and Y27632 were added only on the first and the second day, then only WENR was used.

RNA extraction, library preparation, and transcriptomics

RNA was extracted from human and mouse colon tissues using the PureZOL RNA isolation reagent (Bio-Rad, Hercules, CA, USA, cat. #7326890) according to the manufacturer's instructions. Library preparation and RNA-Seq were performed at the Galseq Srl NGS facility in Milan. For the RNA-Seq, libraries were generated with the NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® and NEBNext® Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ipswich, MA, USA) and sequenced on Illumina HiSeq instrument using a 2x150 paired-end strategy, with a depth of 25 million clusters/sample.

Transcriptomics analyses were performed as previously described[12]. Briefly, FASTQ reads were quality-checked and adaptor-trimmed with Trimmomatic[13] and then mapped to the human hg38 reference genomes with STAR[14]. Differential gene expression and

microbiota abundance were performed with DESeq2[15]. Human functional enrichment analysis was performed with geneSCF[16]. Plots were made with ggplot2[8] or IGV[17]. Raw and processed data were deposited into the NCBI GEO repository with accession number GSE204665.

HBx-induced colitis experiments

8-week-old female C57BL/6 mice were intrarectally injected with 50µl of liposomes conjugated with 1µg/animal of HBx-IRES-GFP- or GFP-encoding plasmids for 20 days. Of note, after about 20 days, the concentration of both plasmids was doubled since mice likely developed resistance to the HBx insult. This is well in line with the concept that HBx, similarly to other viral-derived factors, can coexist with the host because of a sort of immunization process[18]. For HBx silencing *in vivo*, liposome conjugated HBx-targeting or scramble siRNAs were administered every two days by intramucosal injections starting from day 24. The efficacy of the siRNA-mediated HBx silencing was performed in HBx-overexpressing Caco-2 cells undergoing liposome-conjugated siRNA transduction as previously reported[19]. The siRNA sequences are listed in **Supplementary Table 6**. For the experiments, siRNA#3, #7, and #8 were used.

Liposome-conjugated plasmids were made in Opti-MEM™ Reduced Serum Medium (Thermo Fisher Scientific, Waltham, MA, USA, cat. #31985062) using Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher Scientific, Waltham, MA, USA, cat. #11668019) according to the manufacturer's instructions. Injections were performed every other day, for a total of three injections a week. Before each injection, the body weight, presence of gross blood in the feces, and stool consistency were recorded. The DAI was determined by scoring changes in weight loss (0=none, 1=1%–5%, 2=5%–10%, 3=10%–20%, 4=20%), stool consistency (0=normal, 2=loose, 4=diarrhea), and rectal bleeding (0=normal, 2=occult bleeding, 4=gross bleeding). For monitoring colitis, a high-resolution mouse video endoscopic system was developed and used as previously described[20]. At the end of the experiment, mice were sacrificed, colon length was measured, and organs were collected for further analysis.

To deplete the gut microbiota, 8 weeks female C57BL/6 mice were treated with a cocktail of broad-spectrum antibiotics (ampicillin 1g/L, neomycin sulfate 1g/L, vancomycin 0.5g/L, and metronidazole 0.2g/L, Sigma-Aldrich Co. Ltd, MO, USA) dissolved in drinking water for 15 consecutive days, as previously described[21]. The drinking solution was provided ad libitum and renewed every 2 days. On day 10 of antibiotic treatment mice started to receive intrarectal injections of HBx-IRES-GFP- or GFP-encoding plasmids, every 2 days for 15 days, as described in the Supplementary information (“HBx-induced colitis experiments”).

Fluorescence-activated cell sorting (FACS)

Freshly collected UC patient-derived biopsies were incubated in collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ, USA, cat. #LS004177 final concentration: 7.5mg/mL) then smashed in a 100 µm cell strainer (Falcon, Corning, NY, USA, cat. #352360) and 70µm cell strainer (Falcon, Corning, NY, USA, cat. #352350) using complete RPMI 1640 (Lonza, Basel, Switzerland, cat. #12-167Q). Cell suspensions were then washed in Sorting buffer (PBS/HBSS w/o Calcium and Magnesium supplemented with 10% fetal calf serum) and incubated with the Aqua stain Qdot 525 (Thermo Fisher, Waltham, MA, USA, L34957; 0,5:100) at room temperature in the dark for 20 minutes. Cells were sorted to isolate and collect the following mucosal cell populations based on the expression of specific cell markers: Endothelial cells (CD31 FITC; BD Bioscience, Franklin Lakes, NJ, USA, cat. #555545; 20:100), Fibroblasts (CD90 APC; BD Bioscience, Franklin Lakes, NJ, USA, cat. #561971; 5:100), Epithelial cells (EpCAM PE; BD Bioscience, Franklin Lakes, NJ, USA, cat. #347198; 20:100), leukocytes (CD45 PE CF594; BD Bioscience, Franklin Lakes, NJ, USA, cat. #3346961; 2,5:100), CD4⁺ T cells (CD4 PE-Cy7; BD Bioscience, Franklin Lakes, NJ, USA, cat. #557852; 2,5:100) CD8⁺ T cells (CD8 BV780; Biolegend, San Diego, CA, USA, cat. #56382; 0,63:100), B cells (CD20 APC-Cy7; BD Bioscience, Franklin Lakes, NJ, USA, cat. #560734; 2,5:100), Macrophages (CD163 BV650; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563888; 5:100), Myeloid cells (CD11b BV605; BD Bioscience, Franklin Lakes, NJ, USA, cat. #562721; 5:100), Dendritic cells (CD11c BV711; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563130; 5:100), Neutrophils (CD66b; BD Bioscience, Franklin

Lakes, NJ, USA, cat. #562940; 5:100). Soon after the staining, cells were sorted using BD FACS Aria III and DIVA software (BD, Franklin Lakes, NJ, USA) and the different cell populations underwent library preparation and RNA-Seq at the Galseq Srl NGS facility in Milan.

For murine samples, freshly collected colonic mucosa were incubated in collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ, USA, cat. #LS004177 final concentration: 7.5mg/mL) and then smashed in a 100µm cell strainer (Falcon, Corning, NY, USA, cat. #352360) and 70µm cell strainer (Falcon, Corning, NY, USA, cat. #352350) using complete RPMI 1640 (Lonza, Basel, Switzerland, cat. #12-167Q).

The cell suspension was then washed in complete RPMI 1640, and then in FACS Buffer (PBS/HBSS w/o Calcium and Magnesium supplemented with 5% fetal calf serum). Cells were then counted. 1×10^6 cells/colonic cell preparation were incubated with the Aqua stain Qdot 525 (Thermo Fisher, Waltham, MA, USA, L34957; 0,5:100) in the dark for 20 minutes at room temperature. To stain the subpopulations and determine the immunophenotype, the following antibodies were used: Epithelial cells (EpCam PE; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563477; 1:100), Endothelial cells (CD31 BV421; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563356; 3:100), Fibroblasts (CD90 APC; BD Bioscience, Franklin Lakes, NJ, USA, cat. #553007; 0,5:100), Leukocytes (CD45 PE CF594; BD Bioscience, Franklin Lakes, NJ, USA, cat. #562420; 0,625:100), CD4⁺ T cell (CD4 PE-Cy7; BD Bioscience, Franklin Lakes, NJ, USA, cat. #552775; 1,25:100), CD8⁺ T cell (CD8 BV780; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563332; 1,25:100), B Cells (CD20 APC-Cy7; Biolegend, San Diego, CA, USA, cat. #150418; 2:100), Monocytes (Ly6C PerCP Cy5.5; BD Bioscience, Franklin Lakes, NJ, USA, cat. #560525; 1:100), Macrophages (F4/80 BV650; BD Bioscience, Franklin Lakes, NJ, USA, cat. #743282; 1,25:100), Myeloid cells (CD11b BV605; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563015; 0,625:100), Dendritic cells (CD11c BV711; BD Bioscience, Franklin Lakes, NJ, USA, cat. #563048; 1:100), Neutrophils (Ly6G Alexa Fluor 700; BD Bioscience, Franklin Lakes, NJ, USA, cat. #561236; 1:100). Cells were incubated in the dark for 30 minutes at 4°C, followed by fixation and permeabilization with Fixation/Permeabilization solution (Perm/Wash BD, BD Bioscience, Franklin Lakes, NJ, USA, cat. #557885) for 20 minutes at 4°C in the dark. Then anti-GFP Alexa Fluor 488

(Biolegend, San Diego, CA, USA, cat. #3380008; 1:100) was used to amplify the signals from GFP cells. Samples were acquired with BD LSRII Fortessa equipped with Diva Software (BD, Franklin Lakes, NJ, USA). Compensated and biexponentially transformed FCS of acquired samples, singlets, and living cell files (**Supplementary Figures 13A-13C**) were exported for subsequent multidimensional scaling, clustering, and cell-type identification performed through cytoChain[18].

Immunofluorescence analysis

For immunofluorescence analysis of epithelial organoids, the cells were fixed with a solution of PBS with 4% PFA for 30 minutes on ice and then incubated in blocking buffer (PBS1x with 5% with 10% Normal Goat Serum (Thermo Fisher Scientific, Waltham, MA, USA, Cat. #31872) and 0,5% Triton X-100 (Sigma-Aldrich, Darmstadt, Germany, cat. #X100-100mL) 2 hours at room temperature. After washing, cells were incubated with mouse anti-Human EpCam (Santa Cruz Biotechnology, Santa Cruz, CA, USA, cat. #SC-66020; 1:100) and rabbit anti-GFP (Thermo Fisher Scientific, Waltham, MA, USA, cat. #A-21311; 1:500) primary antibodies diluted in blocking buffer overnight at 4°C. Thus, samples were washed and then incubated with secondary antibodies Alexa Fluor 594 dye Goat anti-mouse and Alexa Fluor 488 dye goat anti-rabbit (Thermo Fisher Scientific, Waltham, MA, USA, Cat. #A11005 and #A11034; 1:1.000 both) for 2 hours at room temperature at dark. DAPI (Invitrogen, Waltham, MA, USA, 1:25.000) was added at 5ug/ml concentration in PBS 1x for 15 minutes. Organoids were mounted with Vectashield (Vector Laboratories, Newark, NJ, USA, Cat.#H-1000) on glass and analyzed with a confocal microscope.

Proliferation and permeability assays

For proliferation assay, HBx-IRES-GFP (HBx) transduced and the GFP control Caco-2 cell lines were seeded in 96-well cell culture plates (1×10^3 cells/well) in 10% FBS DMEM medium supplemented with antibiotics. On days 0, 1, 2, and 3 cells were stained with 0.2% crystal violet (Sigma-Aldrich, Darmstadt, Germany, cat. #C0775) dissolved in ethanol. The uptake of dye by cells on plates was eluted with 33% acetic acid in water. Plates were gently shaken for 20 min and the absorbance at 595nm was measured by a

Versamax microplate reader (Molecular Devices). The optical density of each sample was normalized to day 0 of each sample.

For cell permeability assay, HBx and GFP transduced cells were seeded on 0.4µm pore-size Transwell Permeable Supports (Corning Costar, Cambridge, MA, USA, cat. #3401), cultured in a complete culture medium, and allowed to form a monolayer, as previously described[10]. After the establishment of a stable monolayer, cells were assayed for permeability using a Millicell-ERS volt-ohm meter (World Precision Instruments, New Haven, CT) to measure the transepithelial electrical resistance (TEER). The percentage of change in the transendothelial electrical resistance was calculated by comparison with the control cells (GFP).

ChIP, ChIP-Seq analysis

Caco-2 raw sequencing data regarding informative chromatin modifications, CTCF binding profile, and DNA hypersensitivity were downloaded from ENCODE[22]. Chromatin immunoprecipitation, library preparation, and ChIP-Seq were performed at the Galseq Srl NGS facility in Milan. Libraries were generated with the NEBNext® Ultra™ II DNA Library Prep Kit for Illumina® (New England Biolabs, Ipswich, MA, USA) and sequenced on Illumina HiSeq instrument using a 2x150 paired-end strategy, with a depth of 20 million clusters/sample. Computational analysis was performed as previously described[23]. Briefly, FASTQ reads were quality-checked and adaptor-trimmed with Trimmomatic[13] and then mapped to the human hg38 reference genomes with Bowtie2[24]. ChIP peak calling and gene-centric annotation were performed with MACS3[25] and ChIPseeker[26], respectively. Motif discovery was performed with MEME[27]. Chromatin state correlation and Hidden Markov modeling were performed with bamCoverage[28] and ChromHMM[29], respectively. Plots were made with the ggstatplot[30] R package or IGV[17]. Raw and processed data were deposited into the NCBI GEO repository with accession number GSE204665.

Statistical analysis

The sample size was calculated based on the effect size derived from preliminary data. The Shapiro-Wilk normality test assesses homoskedasticity. Dispersions were displayed with `ggplot2`[8] as box plots (median \pm 1.58*IQR/ \sqrt{n}), or trend lines for longitudinal analyses. Differences between the groups were calculated in GraphPad Prism and R, using a two-tailed t-test, one-way ANOVA, or two-way ANOVA, with Tukey's or Bonferroni's post-hoc correction, where appropriate. Multivariate analysis through Pearson's R^2 correlation coefficients and plotting were performed with the `ggstatplot` R package[30]. Tests were considered statistically significant when the P-value \leq 0.05.

Supplementary Tables

Supplementary Table 1. GBIF georeferenced records for *Trichobilharzia*.

Region	n
USA	202
New Zealand	38
Argentina	16
South Africa	13
Canada	11
North America	6
East Boreal	3
France	2
Asia	1
Australia	1

Brazil	1
Iceland	1
United Kingdom	1

Supplementary Table 2. GBIF georeferenced records for *Isatis tinctoria*.

Region	n
France	9101
Germany	5455
Netherlands	4149
Sweden	1558
USA	1437
Switzerland	1096
Spain	831
Italy	548
Belgium	505
Russia	501
Finland	308
Estonia	306
Austria	250
United Kingdom	147
Norway	130
Denmark	107
Ukraine	103
Morocco	93
Turkey	84
Greece	77
Åland	73
Czechia	63
Luxembourg	52

China	40
Canada	28
Romania	25
Croatia	21
Afghanistan	19
Pakistan	17
Portugal	17
Slovakia	16
Poland	12
Armenia	10
Chile	10
Japan	10
Hungary	9
Bulgaria	7
Georgia	7
Algeria	6
Kazakhstan	6
Mongolia	5
Iran	4
North Korea	4
Belarus	3
Kyrgyzstan	3
Moldova	3
Montenegro	3
Serbia	3
New Zealand	2
Slovenia	2
Iceland	1
Ireland	1

Latvia	1
Lebanon	1
North Macedonia	1
Peru	1
South Africa	1

Supplementary Table 3. Functional annotation of the HBx target genes.

ID	Gene Name	Species	GOTERM_BP_DIRECT
FRMD4B	FERM domain containing 4B(FRMD4B)	Homo sapiens	GO:0090162~establishment of epithelial cell polarity,
LUC7L2	LUC7 like 2, pre-mRNA splicing factor(LUC7L2)	Homo sapiens	GO:0006376~mRNA splice site selection,
CREB5	cAMP responsive element binding protein 5(CREB5)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0045893~positive regulation of transcription, DNA-templated,
ESCO1	establishment of sister chromatid cohesion N-acetyltransferase 1(ESCO1)	Homo sapiens	GO:0006275~regulation of DNA replication,GO:0007062~sister chromatid cohesion,GO:0018394~peptidyl-lysine acetylation,GO:0034421~post-translational protein acetylation,
FBLN7	fibulin 7(FBLN7)	Homo sapiens	GO:0007155~cell adhesion,
KBTBD8	kelch repeat and BTB domain containing	Homo sapiens	GO:0006417~regulation of translation,GO:0006513~protein monoubiquitination,GO:0014029~neural crest

	8(KBTBD8)		formation,GO:0014032~neural crest cell development,
LRRCC1	leucine rich repeat and coiled-coil centrosomal protein 1(LRRCC1)	Homo sapiens	GO:0007049~cell cycle,GO:0051301~cell division,
MUC17	mucin 17, cell surface associated(MUC 17)	Homo sapiens	GO:0019725~cellular homeostasis,
PDE4D	phosphodiesterase 4D(PDE4D)	Homo sapiens	GO:0002027~regulation of heart rate,GO:0006198~cAMP catabolic process,GO:0007165~signal transduction,GO:0010469~regulation of receptor activity,GO:0010880~regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0019933~cAMP-mediated signaling,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0045822~negative regulation of heart contraction,GO:0050852~T cell receptor signaling pathway,GO:0060314~regulation of ryanodine-sensitive calcium-release channel activity,GO:0061028~establishment of endothelial barrier,GO:0071320~cellular

			<p>response to cAMP,GO:0071872~cellular response to epinephrine stimulus,GO:0071875~adrenergic receptor signaling pathway,GO:0086004~regulation of cardiac muscle cell contraction,GO:0086024~adrenergic receptor signaling pathway involved in positive regulation of heart rate,GO:1901844~regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1901898~negative regulation of relaxation of cardiac muscle,</p>
PDGFRA	platelet derived growth factor receptor alpha(PDGFR α)	Homo sapiens	<p>GO:0001553~luteinization,GO:0001701~in utero embryonic development,GO:0001775~cell activation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007275~multicellular organism development,GO:0008210~estrogen metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0010544~negative regulation of platelet activation,GO:0010863~positive regulation of phospholipase C activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030198~extracellular matrix organization,GO:0030324~lung development,GO:0030325~adrenal gland development,GO:0030335~positive regulation of cell migration,GO:0030539~male genitalia development,GO:0033327~Leydig cell</p>

			<p>differentiation,GO:0033674~positive regulation of kinase activity,GO:0034614~cellular response to reactive oxygen species,GO:0035790~platelet-derived growth factor receptor-alpha signaling pathway,GO:0038091~positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042475~odontogenesis of dentin-containing tooth,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0046777~protein autophosphorylation,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048015~phosphatidylinositol-mediated signaling,GO:0048146~positive regulation of fibroblast proliferation,GO:0048557~embryonic digestive tract morphogenesis,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048704~embryonic skeletal system morphogenesis,GO:0050872~white fat cell differentiation,GO:0050920~regulation of chemotaxis,GO:0055003~cardiac myofibril assembly,GO:0060021~palate development,GO:0060325~face morphogenesis,GO:0060326~cell chemotaxis,GO:0061298~retina vasculature development in camera-type eye,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070527~platelet aggregation,GO:0071230~cellular response to amino acid stimulus,GO:0072277~metanephric glomerular capillary formation,GO:2000249~regulation of actin cytoskeleton reorganization,GO:2000739~regulation of</p>
--	--	--	--

			mesenchymal stem cell differentiation,
SLC22A11	solute carrier family 22 member 11(SLC22A11)	Homo sapiens	GO:0015698~inorganic anion transport,GO:0015711~organic anion transport,GO:0046415~urate metabolic process,GO:0055085~transmembrane transport,

SHH	sonic hedgehog signaling molecule(SHH)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001570~vasculogenesis,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001708~cell fate specification,GO:0001755~neural crest cell migration,GO:0001947~heart looping,GO:0002052~positive regulation of neuroblast proliferation,GO:0002076~osteoblast development,GO:0002320~lymphoid progenitor cell differentiation,GO:0003140~determination of left/right asymmetry in lateral mesoderm,GO:0006897~endocytosis,GO:0007224~smoothened signaling pathway,GO:0007228~positive regulation of hh target transcription factor activity,GO:0007267~cell-cell signaling,GO:0007389~pattern specification process,GO:0007398~ectoderm development,GO:0007405~neuroblast proliferation,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0007418~ventral midline development,GO:0007442~hindgut morphogenesis,GO:0007507~heart development,GO:0007596~blood coagulation,GO:0008209~androgen metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0009880~embryonic pattern specification,GO:0009949~polarity specification of anterior/posterior axis,GO:0009953~dorsal/ventral pattern formation,GO:0010468~regulation of gene expression,GO:0010628~positive regulation of
------------	--	--------------	---

			<p>gene expression,GO:0010629~negative regulation of gene expression,GO:0014003~oligodendrocyte development,GO:0014706~striated muscle tissue development,GO:0014858~positive regulation of skeletal muscle cell proliferation,GO:0014902~myotube differentiation,GO:0016539~intein-mediated protein splicing,GO:0016540~protein autoprocessing,GO:0021513~spinal cord dorsal/ventral patterning,GO:0021522~spinal cord motor neuron differentiation,GO:0021794~thalamus development,GO:0021904~dorsal/ventral neural tube patterning,GO:0021930~cerebellar granule cell precursor proliferation,GO:0021938~smoothed signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation,GO:0021978~telencephalon regionalization,GO:0030010~establishment of cell polarity,GO:0030162~regulation of proteolysis,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030324~lung development,GO:0030326~embryonic limb morphogenesis,GO:0030336~negative regulation of cell migration,GO:0030539~male genitalia development,GO:0030850~prostate gland development,GO:0030878~thyroid gland development,GO:0030900~forebrain development,GO:0030901~midbrain development,GO:0030902~hindbrain development,GO:0031016~pancreas development,GO:0031069~hair follicle morphogenesis,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0033077~T cell</p>
--	--	--	--

			differentiation in thymus,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0033092~positive regulation of immature T cell proliferation in thymus,GO:0034244~negative regulation of transcription elongation from RNA polymerase II promoter,GO:0034504~protein localization to nucleus,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0042127~regulation of cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0042307~positive regulation of protein import into nucleus,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042481~regulation of odontogenesis,GO:0042733~embryonic digit morphogenesis,GO:0043010~camera-type eye development,GO:0043066~negative regulation of apoptotic process,GO:0043369~CD4-positive or CD8-positive, alpha-beta T cell lineage commitment,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045109~intermediate filament organization,GO:0045445~myoblast differentiation,GO:0045596~negative regulation of cell differentiation,GO:0045880~positive regulation of smoothed signaling pathway,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046638~positive regulation of alpha-beta T cell differentiation,GO:0046639~negative regulation of alpha-beta T cell differentiation,GO:0048468~cell
--	--	--	---

			<p>development,GO:0048538~thymus development,GO:0048557~embryonic digestive tract morphogenesis,GO:0048617~embryonic foregut morphogenesis,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0048645~animal organ formation,GO:0048663~neuron fate commitment,GO:0048706~embryonic skeletal system development,GO:0048709~oligodendrocyte differentiation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0048745~smooth muscle tissue development,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048839~inner ear development,GO:0048859~formation of anatomical boundary,GO:0048864~stem cell development,GO:0051155~positive regulation of striated muscle cell differentiation,GO:0051781~positive regulation of cell division,GO:0060020~Bergmann glial cell differentiation,GO:0060021~palate development,GO:0060070~canonical Wnt signaling pathway,GO:0060174~limb bud formation,GO:0060428~lung epithelium development,GO:0060439~trachea morphogenesis,GO:0060445~branching involved in salivary gland morphogenesis,GO:0060447~bud outgrowth involved in lung branching,GO:0060458~right lung development,GO:0060459~left lung development,GO:0060463~lung lobe morphogenesis,GO:0060484~lung-associated mesenchyme development,GO:0060516~primary prostatic bud elongation,GO:0060523~prostate epithelial cord elongation,GO:0060662~salivary</p>
--	--	--	--

			<p>gland cavitation,GO:0060664~epithelial cell proliferation involved in salivary gland morphogenesis,GO:0060685~regulation of prostatic bud formation,GO:0060738~epithelial-mesenchymal signaling involved in prostate gland development,GO:0060769~positive regulation of epithelial cell proliferation involved in prostate gland development,GO:0060782~regulation of mesenchymal cell proliferation involved in prostate gland development,GO:0060783~mesenchymal smoothed signaling pathway involved in prostate gland development,GO:0060840~artery development,GO:0060916~mesenchymal cell proliferation involved in lung development,GO:0061053~somite development,GO:0061189~positive regulation of sclerotome development,GO:0071285~cellular response to lithium ion,GO:0071542~dopaminergic neuron differentiation,GO:0072136~metanephric mesenchymal cell proliferation involved in metanephros development,GO:0072205~metanephric collecting duct development,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090370~negative regulation of cholesterol efflux,GO:0097190~apoptotic signaling pathway,GO:1900175~regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry,GO:1900180~regulation of protein localization to nucleus,GO:1904339~negative regulation of dopaminergic neuron differentiation,GO:1905327~tracheoesophageal septum formation,GO:2000062~negative</p>
--	--	--	---

			<p>regulation of ureter smooth muscle cell differentiation,GO:2000063~positive regulation of ureter smooth muscle cell differentiation,GO:2000357~negative regulation of kidney smooth muscle cell differentiation,GO:2000358~positive regulation of kidney smooth muscle cell differentiation,GO:2000729~positive regulation of mesenchymal cell proliferation involved in ureter development,GO:2001054~negative regulation of mesenchymal cell apoptotic process,</p>
--	--	--	--

TRIP13	thyroid hormone receptor interactor 13(TRIP13)	Homo sapiens	GO:0001556~oocyte maturation,GO:0006302~double-strand break repair,GO:0006355~regulation of transcription, DNA-templated,GO:0006366~transcription from RNA polymerase II promoter,GO:0007094~mitotic spindle assembly checkpoint,GO:0007130~synaptonemal complex assembly,GO:0007131~reciprocal meiotic recombination,GO:0007141~male meiosis I,GO:0007144~female meiosis I,GO:0007283~spermatogenesis,GO:0007286~spermatid development,GO:0048477~oogenesis,GO:0051598~meiotic recombination checkpoint,
TMEM242	transmembrane protein 242(TMEM242)	Homo sapiens	GO:0033615~mitochondrial proton-transporting ATP synthase complex assembly,
TUBB2B	tubulin beta 2B class IIb(TUBB2B)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0001764~neuron migration,GO:0007017~microtubule-based process,GO:0050804~modulation of synaptic transmission,GO:1902669~positive regulation of axon guidance,GO:1990403~embryonic brain development,
ZCCHC7	zinc finger CCHC-type containing 7(ZCCHC7)	Homo sapiens	

Supplementary Table 4. List of primer pairs for gene expression analysis of murine samples.

	Gene name	Forward sequence	Reverse sequence
Primers	<i>Il1b</i>	AGTTGACGGACCCCAAAA	AGCTGGATGCTCTCATCAGG
	<i>Il6</i>	TAGTCCTCCCTACCCCAATTC	TTGGTCCTTAGCCACTCCTTC
	<i>Tnfa</i>	GCCTGTAGCCCACGTCGTAG	TCCTCCACTTGGTGGTTTG
	<i>Notch1</i>	GATGGCCTCAATGGGTACAAG	TCGTTGTTGTTGATGTCACAGT
	<i>Tlr6</i>	AGCCAAGACAGAAAACCCATC	GGGGTCATGCTCCGACTAT
	<i>Tlr4</i>	ATGGCATGGCTTACACCACC	GAGGCAATTTTGTCTCCACA
	<i>Muc1</i>	TACCCTACCTACCACACTCAG	CTGCTACTGCCATTACCTGC
	<i>Muc13</i>	AGGGAGGGAGAAGGTAGCAG	GCTTTTGTGGCTTTCCAGG
	<i>Tjp1</i>	GGAGCAGGCTTTGGAGGAG	TGGGACAAAAGTCCGGAAG
	<i>Gapdh</i>	CGTGTTCTACCCCAATGT	TGTCATCATACTTGGCAGGTT

Supplementary Table 5. List of primer pairs for gene expression analysis of human samples.

	Gene name	Forward sequence	Reverse sequence
C	<i>CLDN1</i>	CAGAGCACCGGGCAGATCCA	GGCACGGGTTGCTTGCAATG
	<i>CLDN2</i>	CTGAGCTCACAGGCCATTCA	CCACAAGCAGCCTCAAGAAG
	<i>CLDN3</i>	CACTGCCACAGGACCTTCAG	AGGATGGCCACCACGATGA

	CLDN4	GCAACATTGTCATCACCTCGCAG	ACACCTTGCACTGCATCTGG
	OCLM	CACCTCCTTACAGGCCTGAT	GAGTAGGCTGGCTGAGAGA
	TJP1	ACCAGTAAGTCGTCTGATCC	TCGGCCAAATCTTCTCACTCC
	GAPDH	CATGAGAAGTATGACAACAGC	AGTCCTTCCACGATACCAAAG

Supplementary Table 6. List of HBx-targeting siRNA sequences.

	HBx gene target sequence
HBx.siRNA1	UUGACAUUGCUGAGAGUCCAA
HBx.siRNA2	UAUGCCUCAAGGUCGGUCGUU
HBx.siRNA3	UUUAAACAAACAGUCUUUGAA
HBx.siRNA4	UCGGUCGUUGACAUUGCUGAG
HBx.siRNA5	UUCACGGUGGUCUCCAUGCGA
HBx.siRNA6	AGUCUUUAAACAAACAGUCUU
HBx.siRNA7	UCUUUAAACAAACAGUCUUUG
HBx.siRNA8	UUAAACAAACAGUCUUUGAAG

Supplementary Table 7. WENR culturing medium composition.

Compound	Stock Mol/L	Final Mol/L	Final Volume (mL) in 100 ml	Company; cat. #

WNT3a	2	1	50	ATCC; cat. #CRL-2647
R- Spondin	5	1	20	Kindly provided by Leland Stanford Junior University; Prof. Brian Huang
Nogging	10	1	10	Kindly provided byHubrecht Insitute; Prof. J. den Hertog
B27	50	1	2	LifeTechnologies; 17504044
N2	100	1	1	LifeTechnologies; 17502001
NAC	0.5	0.001	0.2	Sigma-Aldrich; A7250
Nicotinamide	1	0.01	1	Sigma-Aldrich; 72340-100
A83-01	0.005	0.0000005	0.01	Tocris; 2939
SB431514	0.01	0.000001	0.01	Tocris; 1614
SB202190	0.03	0.000003	0.01	Tocris; 1264
EGF	0.1	0.00005	0.05	Peprrotech AF-100-15
Prostaglandin E2	0.001	0.0000001	0.001	Tocris; 2296
Gastrin	0.0001	0.00000001	0.01	Tocris; 3006
Advanced DMEM/F12			16	Lonza; #BE04687F/1

References

- 1 Edgar RC, Taylor J, Lin V, *et al.* Petabase-scale sequence alignment catalyses

- viral discovery. *Nature* 2022;602:142–7. doi:10.1038/s41586-021-04332-2
- 2 Soldánová M, Selbach C, Sures B. The Early Worm Catches the Bird? Productivity and Patterns of *Trichobilharzia szidati* Cercarial Emission from *Lymnaea stagnalis*. *PLoS ONE* 2016;11:e0149678. doi:10.1371/journal.pone.0149678
 - 3 Gulyás K, Soldánová M, Orosová M, *et al.* Confirmation of the presence of zoonotic *Trichobilharzia franki* following a human cercarial dermatitis outbreak in recreational water in Slovakia. *Parasitol Res* 2020;119:2531–7. doi:10.1007/s00436-020-06751-y
 - 4 Tennant BC, Gerin JL. The woodchuck model of hepatitis B virus infection. *ILAR J* 2001;42:89–102. doi:10.1093/ilar.42.2.89
 - 5 Ng SC, Shi HY, Hamidi N, *et al.* Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017;390:2769–78. doi:10.1016/S0140-6736(17)32448-0
 - 6 Kobayashi T, Siegmund B, Le Berre C, *et al.* Ulcerative colitis. *Nat Rev Dis Primers* 2020;6:74. doi:10.1038/s41572-020-0205-x
 - 7 Altschul SF, Gish W, Miller W, *et al.* Basic local alignment search tool. *J Mol Biol* 1990;215:403–10. doi:10.1016/S0022-2836(05)80360-2
 - 8 Ginestet C. ggplot2: Elegant Graphics for Data Analysis. *J Royal Statistical Soc A* 2011;174:245–6. doi:10.1111/j.1467-985X.2010.00676_9.x
 - 9 Wickham H, Averick M, Bryan J, *et al.* Welcome to the tidyverse. *JOSS* 2019;4:1686. doi:10.21105/joss.01686
 - 10 Ungaro F, Tacconi C, Massimino L, *et al.* MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. *Gastroenterology* 2017;153:1363-1377.e6. doi:10.1053/j.gastro.2017.07.048
 - 11 Dull T, Zufferey R, Kelly M, *et al.* A third-generation lentivirus vector with a conditional packaging system. *J Virol* 1998;72:8463–71. doi:10.1128/JVI.72.11.8463-8471.1998
 - 12 Ungaro F, Massimino L, Furfaro F, *et al.* Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. *Gut Microbes* 2019;10:149–58. doi:10.1080/19490976.2018.1511664
 - 13 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–20. doi:10.1093/bioinformatics/btu170
 - 14 Dobin A, Davis CA, Schlesinger F, *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21. doi:10.1093/bioinformatics/bts635

- 15 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550. doi:10.1186/s13059-014-0550-8
- 16 Subhash S, Kanduri C. GeneSCF: a real-time based functional enrichment tool with support for multiple organisms. *BMC Bioinformatics* 2016;17:365. doi:10.1186/s12859-016-1250-z
- 17 Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinformatics* 2013;14:178–92. doi:10.1093/bib/bbs017
- 18 Virgin HW. The virome in mammalian physiology and disease. *Cell* 2014;157:142–50. doi:10.1016/j.cell.2014.02.032
- 19 Ungaro F, Colombo P, Massimino L, *et al.* Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. *Int J Cancer* 2019;145:1913–20. doi:10.1002/ijc.32286
- 20 D'Alessio S, Correale C, Tacconi C, *et al.* VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. *J Clin Invest* 2014;124:3863–78. doi:10.1172/JCI72189
- 21 Tan J, Gong J, Liu F, *et al.* Evaluation of an antibiotic cocktail for fecal microbiota transplantation in mouse. *Front Nutr* 2022;9:918098. doi:10.3389/fnut.2022.918098
- [dataset] 22 ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012;489:57–74. doi:10.1038/nature11247
- 23 Sessa A, Fagnocchi L, Mastrototaro G, *et al.* SETD5 Regulates Chromatin Methylation State and Preserves Global Transcriptional Fidelity during Brain Development and Neuronal Wiring. *Neuron* 2019;104:271-289.e13. doi:10.1016/j.neuron.2019.07.013
- 24 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012;9:357–9. doi:10.1038/nmeth.1923
- 25 Gaspar JM. Improved peak-calling with MACS2. *BioRxiv* Published Online First: 17 December 2018. doi:10.1101/496521
- 26 Yu G, Wang L-G, He Q-Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics* 2015;31:2382–3. doi:10.1093/bioinformatics/btv145
- 27 Bailey TL, Boden M, Buske FA, *et al.* MEME SUITE: tools for motif discovery and searching. *Nucleic Acids Res* 2009;37:W202-8. doi:10.1093/nar/gkp335
- 28 Ramírez F, Dündar F, Diehl S, *et al.* deepTools: a flexible platform for exploring deep-sequencing data. *Nucleic Acids Res* 2014;42:W187-91.

doi:10.1093/nar/gku365

- 29 Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods* 2012;9:215–6. doi:10.1038/nmeth.1906
- 30 Patil I. Visualizations with statistical details: The “ggstatsplot” approach. *JOSS* 2021;6:3167. doi:10.21105/joss.03167

Supplementary figure legends

Supplementary Figure 1. HBx was detected in specific mucosal cell populations from UC patients. (A) Schematic experimental workflow for the sorting of the indicated cell populations from UC patient-derived colonic mucosae (n=24 total samples). (B) Gating strategy to isolate live, epithelial cells, CD4⁺ T cells and macrophages, B and CD8⁺ T cells, dendritic cells, fibroblast, and endothelial cells, as indicated in each plot. (C) HBV genome (Genes S, P, X, and C) mapping of FASTQ reads from RNA-Seq detects HBx transcript only in CD8⁺ T cells, dendritic cells, endothelium, epithelium, and macrophages. (D) Schematic representation of the Touchdown PCR (starting at 68°C and ending at an annealing temperature of 62°C) amplification cycles. (E) Gel electrophoresis image showing HBx amplicon in a representative cohort of UC patients (UC 1, 2, 3, 4, 5, 6 patients at their first screening). “+” sample symbol indicates the HBx⁺ UC patient tested in the previously published work(12) GAPDH was used as an internal control. (F) Representative read from Sanger sequencing showing perfect amplicon alignment to the HBx reference sequence.

Supplementary Figure 2. HBx correlates with no UC clinical parameters.

Correlation heatmap showing multivariate analysis results expressed as Pearson coefficients (from 1 to -1). Xs mark non-significant at P<0.05 (Adjustment: Holm). The analysis was performed on UC patients recruited at Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.

Supplementary Figure 3. HBx overexpression in colonic mucosa activates proinflammatory biological processes.

(A) Schematic experimental workflow of healthy colonic biopsies (n=3 healthy donors) transduction with HBx followed by RNA-Seq. (B) MA plot showing differentially expressed genes between HBx-overexpressing colonic biopsies and the GFP-transduced controls. Red and blue indicate statistically significant up- and down-regulated genes, respectively. (C) GO plot showing dysregulated biological processes in HBx-transduced biopsies by comparison with GFP. Icons from Streamline (<https://app.streamlinehq.com>).

Supplementary Figure 4. HBx induces mucosal barrier damage *in vivo*.

(A, B) Representative images of endoscopy performed in GFP- (A) and HBx-treated (B) mice. (C, D) Graph showing statistically significant differences in stool consistency (C) and bleeding scores (D) in GFP- and HBx-treated mice. Statistical analysis was performed with Two-way ANOVA, with Bonferroni's post-correction.

Supplementary Figure 5. HBx induces colitis with no contributions by the microbiota. (A) Schematic experimental workflow of *in vivo* HBx-induced colitis (n=5-8/group). (B) Disease Activity Index (DAI) of mice treated with either GFP- or HBx-carrying liposomes with or without antibiotic treatment. (C, D) Box plots showing colon length (C) and endoscopic scores (D) of HBx-induced colitic mice with or without antibiotic treatment. (E) Representative images of endoscopy performed in GFP- and HBx-treated mice with or without antibiotic treatment. Statistical analysis was performed with Two-way ANOVA, with Bonferroni's post-correction. *P<.05; **P<.01; ***P<.005; ****P<.001

Supplementary Figure 6. HBx shapes colonic mucosal immunity.

Relative cell population abundance in HBx-induced colitis mice versus the GFP control quantified by FACS analysis.

Supplementary Figure 7. HBx regulates the expression of UC-related genes by binding enhancer regions.

(A, B) Integrative Genome Viewer (IGV) screenshots for two representative loci showing HBx peak localization, together with all other ChIP-Seq signals.

Supplementary Figure 8. HBx silencing re-establishes the barrier functions and reduces proinflammatory phenotype *in vitro*.

(A) Box plots showing the HBx expression level in HBx-transduced Caco-2 upon the indicated siRNA administration. (B) Graph showing cellular growth rate between HBx- and GFP-transduced epithelial cell line upon either the HBx-targeting siRNA administration or the scramble control. Experiments were performed in triplicates in three independent experiments. (C) Box plots showing Transepithelial Electrical Resistance (TEER, expressed as Ω/cm^2) measurements on HBx- and GFP-transduced epithelial cell lines upon either the HBx-targeting siRNA administration or the scramble control. (D) Box plots showing Real-Time PCR results for the epithelial barrier markers in Caco-2 cells transduced with either the GFP- or HBx-carrying lentiviruses upon HBx-targeting siRNA administration or the scramble control, expressed as $2^{-\Delta\text{CT}}$ (GAPDH was used as the housekeeping genes). Statistical analysis was performed with One-way or Two-way Anova with Bonferroni's post-correction. *P<.05; **P<.01; ***P<.005; ****P<.001.

Supplementary Figure 9. HBx silencing restores the gut mucosa *in vivo*.

(A, B) Representative images of endoscopy performed in GFP (A) and HBx-induced (B) colitic mice treated with scramble or HBx-targeting siRNAs. (C, D) Graph showing stool consistency (C) and bleeding scores (D) in GFP and HBx-induced colitic mice treated with scramble or HBx-targeting siRNAs. Statistical analysis was performed with Two-way ANOVA, with Bonferroni's post-correction. Results with a P-value<0.05 were considered significant.

Supplementary Figure 10. HBx silencing re-establishes the barrier functions and reduces proinflammatory phenotype *in vivo*.

(A-C) Box plots showing relative expression of genes related to the epithelial barrier (A), anti-microbial response (B), and pro-inflammatory response (C) in the colonic mucosa of GFP and HBx liposome-transduced mice upon HBx-targeting siRNA administration of scramble control. Expression levels are expressed as $2^{-\Delta\text{Ct}}$; GAPDH was used as the housekeeping gene. N=3/group, 2 independent experiments. Statistical analysis was performed with Two-way ANOVA, with Tukey's post-correction. *P indicates the comparison HBx versus GFP; §P indicates the comparison HBx versus siRNA HBx; *P<.05; **P<.005.

Supplementary Figure 11. The *Hepadnaviridae* family is detected in different organisms.

(A) Schematic representation of the computational query for *Hepadnaviridae* reads within the Serratus database (DB). (B) Bar graph showing the relative number of positive reads per species, color-coded for macro categories. Icons from Streamline (<https://app.streamlinehq.com>).

Supplementary Figure 12. HBx BLAST alignments and biodiversity data of *Trichobilharzia* and *Isatis tinctoria*.

(A) Schematic representation of the computational workflow. The reads found to be positive for *Hepadnaviridae* in the Serratus DB were mapped to the HBx reference sequence with NCBI BLAST. (B-E) *Trichobilharzia* (B) and *Isatis Tinctoria* (C) read alignment to the HBx reference sequence. No alignment was found when the mapping was attempted with the reads belonging to *Odorrona tormota* (D), or *Elaeagnaceae* (E). (F-G) Map of georeferenced record observations of *Trichobilharzia* (F) and *Isatis Tinctoria* (G) from the Global Biodiversity Information Facility (GBIF), representative of their global distribution. Icons from Streamline (<https://app.streamlinehq.com>).

Supplementary Figure 13. FACS analysis of HBx-treated mice.

(A-C) Gating strategy to isolate live cells prior to downstream immune profiling with cytoChain.